×

Biotech and Pharmaceuticals Pharmaceuticals

  • Dog with headache

    Aimovig from Amgen and Novartis could become a $1 billion to $2 billion business in five years, say one Wall Street analyst.

  • LONDON, May 18- More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed...

  • Dr. Scott Gottlieb

    Major pharmaceutical companies have spent billions of dollars in an effort to patent their products and avoid generic copies of blockbuster medicines, but the FDA commissioner has vowed to end this, the New York Times reports.

  • LONDON, May 18- AstraZeneca's first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018.. Core operating profit tumbled 46 percent to $896 million, well below market forecasts, and Crestor sales...

  • LONDON, May 18- AstraZeneca's first quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018.. Core operating profit tumbled 46 percent to $896 million, well below market forecasts, and Crestor sales...

  • Generic competition to cholesterol fighter Crestor and higher costs hit AstraZeneca in the first quarter.

  • May 17- Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults. The drug, Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month, the company said. Some Wall Street analysts had expected a price as high as $10,000 a year.

  • May 17- Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults. The drug, Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month, the company said. Some Wall Street analysts had expected a price as high as $10,000 a month.

  • *American Thoracic Society meeting crucial for GSK. The British drugmaker has dominated the lung drug market for decades, but its pre-eminence is no longer guaranteed, given declining sales of the aging Advair inhaler, which could soon face generic competition in the United States. That makes this year's meeting of the American Thoracic Society from May 18 to...

  • Dr. Kenneth Davis

    The Trump administration should address the high cost of prescription drugs in trade negotiations, Mt. Sinai CEO Kenneth Davis says.

  • But many of the companies immediately pushed back, saying the FDA list of drugmakers may be out of date and that some of the drugs included on it already have generic competitors. The FDA said the list contained all of the inquiries about drugs it had received from generic drugmakers since 2005. The agency said companies on the list may be using FDA safety...

  • The FDA said Thursday that brand-name drugmakers sometimes refuse to sell generic companies drugs that may need extra safety monitoring or bar drug wholesalers from selling other medicines to generic drugmakers. "We hope that this increased transparency will help reduce unnecessary hurdles to generic drug development and approval," the FDA said in a...

  • The public feels strongly about doing something on drug prices and wants to see action, said Tricia Neuman, senior vice president and director of the program on Medicare policy at the foundation. Some of the ideas might help, but the plan bypasses an obvious remedy- one that President Donald Trump embraced as a candidate: allowing Medicare to negotiate drug...

  • May 17- The U.S. Food and Drug Administration on Thursday listed drugmakers, including Celgene Corp, Mylan NV, Gilead Sciences and Novartis AG, who the regulator says are potentially blocking access to samples of their drugs to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products,...

  • Michael Cohen, personal lawyer for President-elect Donald Trump.

    Roche has had no contact with U.S. President Donald Trump's personal attorney Michael Cohen, said company Chief Executive Severin Schwan.

  • May 17- The U.S. Food and Drug Administration on Thursday named drugmakers including Celgene Corp, Mylan NV, Gilead Sciences and Novartis AG for potentially blocking access to samples of their products to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products, the FDA said.

  • *Promising data from early drug trial stages. FRANKFURT, May 17- Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping efforts to find a drug-industry partner to share further development costs for one of them. "Merck will not have a problem finding a partner with this...

  • JOHANNESBURG, May 17- Aspen Pharmacare, Africa's biggest generic drugmaker, said on Thursday it had secured a 3.4 billion euro credit facility for refinancing debt at three of its subsidiaries. Aspen, which has operations in 50 countries, said the facilities were 70 percent oversubscribed and would be used for Aspen Finance, Pharmacare Limited t/a Aspen...

  • *Takeda boss to raise bar for pipeline drugs after Shire deal. LONDON, May 17- For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit. When you combine two pipelines you can be more stringent, "he said in London, where he is meeting investors and analysts.

  • *Promising data from early drug trial stages. FRANKFURT, May 17- Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping efforts to find drug-industry partners to share further development costs. "Merck will not have a problem finding a partner with this data set," said...